21/03/2021 - General information
March 21st is World Down Syndrome Day and we are joining in by launching the "21 reasons to collaborate with science" campaign. The goal is to promote clinical research into people with Down's syndrome, to encourage them to get involved in the clinical studies that are currently being carried out and, in this way, to help improve the health and quality of life of these people. Through the 21 reasons campaign, the team of Dr. Rafael de la Torre, director of the Neurosciences research programme at the Hospital del Mar Medical Research Institute, wants to raise awareness and encourage people with Down syndrome to get involved in the studies they are conducting. According to Dr. de la Torre, "The therapeutic approach to these people, given their genetic features, has been quite specific, and the more knowledge we have, the more we will be able to adjust the therapy to their needs. Certain medical practices should also be studied in individuals with this syndrome."
21/03/2021 - General information
Down syndrome (DS) is the most common chromosomal abnormality in children leading to lifelong intellectual disability. Over one million people in the EU and US have DS, and its prevalence has increased in the last ten years. Thanks to significant advances in medical and social care, the life expectancy of individuals with DS has increased greatly, so that many of them reach even the age of 60-70. DS causes lifelong cognitive dysfunction, which results in important negative consequences for these individuals, their families and society. Despite the heavier social burden and the greater medical needs linked to this intellectual disability, there isn't an approved therapy for DS-related cognitive dysfunction yet. Furthermore, though there are specific cognitive screening tests designed for individuals with DS, no official guidelines have been developed to assess their cognitive deficits or their impact on quality of life of DS individuals and their families.
03/12/2020 - General information
The Catalonian Antidoping Laboratory first obtained the ISO17025 accreditation 20 years ago, in November 2000. The laboratory has been accredited as an anti-doping laboratory since 1985 and is one of 30 laboratories in the world accredited by the World Anti-Doping Agency (WADA). The ISO17025 accreditation of all analytical procedures applied in doping controls was a prerequisite for maintaining doping accreditation from 2001 onwards. ISO17025 is an internationally recognised quality standard designed to guarantee the technical competence of testing laboratories, in other words, to ensure that laboratories deliver accurate, reliable results. In Spain, ISO17025 accreditation is awarded by ENAC (Entidad Nacional de Acreditación), a Spanish Government body.
Més informació "The Catalonian Antidoping Laboratory celebrates 20 years of ISO17025 accreditation."
10/11/2020 - General information
The director of the Neuropsychiatry and Addictions Institute at Hospital del Mar and coordinator of the Mental Health Research Group at the Hospital del Mar Medical Research Institute will be the president of the organisation for the next four years. Up to now, he has been the Vice-president of the society. Dr. Víctor Pérez, Director of the Institute of Neuropsychiatry and Addictions (INAD) at Hospital del Mar, will be the President of the Spanish Society of Biological Psychiatry (Sociedad Española de Psiquiatría Biológica; SEPB) for the next four years. He was elected at the society's Ordinary General Assembly, held virtually on 29 October.
05/11/2020 - General information
The ICOD (Improving Cognition in Down Syndrome) project is being coordinated by the Integrated Pharmacology and Systems Neuroscience Research Group, led by Dr. Rafael de la Torre. It will trial a new therapy to treat cognitive deficits in Down Syndrome sufferers. Six institutions from Spain, France and Italy are taking part. A project led by the Hospital del Mar Medical Research Institute (IMIM), has received a six million euro development grant from the European Commission. The Improving Cognition in Down Syndrome (ICOD) project was one of 75 projects selected within the European Union's Horizon 2020 research and innovation programme. Only nine projects coordinated by Catalan organisations will benefit from these grants, in the last year they are being awarded.
01/10/2020 - General information
Each year, around 20 million European citizens are affected from depression. Depression is a serious illness which impacts on all aspects of life, including work. While Small and Medium Sized enterprises particularly face substantial economic losses due to the global impact of COVID-19, the MENTUPP consortium anticipates, that capacities for mental health promotion and provision in Small and Medium Enterprises (SMEs) will be even more limited in the future. A second COVID-19 wave might further impact negatively on people affected by depression. This is why action on occupational mental health is urgently needed. Resources for Small and Medium Sized Enterprises "Limited capacities for mental health promotion and provision of adequate occupational mental health programmes for employees are a concern shared by most decision-makers in Small and Medium Sized Enterprises (SMEs)", says Prof. Ella Arensman, Coordinator of the MENTUPP project. In the EU, these businesses contribute to more than 90% of the economy. Particularly, SMEs in the construction, healthcare and Information and Communications Technology (ICT) sectors have been associated with higher risk of mental health difficulties compared to other sectors. COVID-19 has significant short-term and long-term effects on the mental health people working in these sectors.
Més informació "EU-funded Mental Health Promotion and Intervention in Occupational Settings"
30/06/2020 - General information
The successful projects are "Obtaining antioxidant active substances from the carob pod and validating their therapeutic potential", which involves the company Euronutra, the IBIMA (Malaga Biomedical Research Institute), the IMIM (Hospital del Mar Medical Research Institute), and the CRG (Centre for Genomic Regulation); and the project "Development of a new therapy for Fragile X syndrome", in which the company Connecta Therapeutics, the IMIM, and the CRG are participating. The Spanish Innovation Agency call for these grants is part of the State Plan for Scientific and Technical Research and Innovation 2017-2020. The goal is to finance cooperative projects between companies and research bodies in order to carry out joint R&D projects that are close to the market and that, due to their subject matter, are aligned with the priorities established in the challenges of the State R&D Programme Oriented to the Challenges of Society. This year's call has a budget of 260 million euros and one of the requirements is that the coordinator applying for the grant must be a company.
10/06/2020 - General information
The Director of the Addictions Process Group within the Institute of Neuropsychiatry and Addictions at the Hospital del Mar (INAD) and a researcher at the Hospital del Mar Medical Research Institute (IMIM) has participated in the drafting of this document, which analyses the different treatments and establishes the standards of use for the entire world. The guide was presented in March at the 63rd session of the Commission on Narcotic Drugs 2020, held at the United Nations Office in Vienna. In March, the United Nations, through its Office on Drugs and Crime (UNODC), and the World Health Organisation (WHO), jointly approved the first International standards for the treatment of drug use disorders. This document was written with the assistance of leading experts in this field, including Dr. Marta Torrens, Director of the Addictions Process Group at INAD and coordinator of the Addictions Research Group at the Hospital del Mar Medical Research Institute (IMIM). Dr. Torrens is the only author from Spain.
01/12/2015 - General information
The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade. This agency aims to provide objective and reliable information concernint drugs and their consequences.
Més informació "New EMCDDA report explores combined mental health and substance use disorders"
27/11/2012 - General information
Two studies led by researchers from the neuroimaging research group at IMIM led by Òscar Vilarroya, and which also involved researchers from UAB and the Hospital de la Vall d’Hebron, have been cited in the “Consensus Report of the APA Work Group” as international reference works in the area of attention deficit and hyperactivity disorder (ADHD), conferring upon these researchers the status of world leaders in this field.
Més informació "IMIM researchers world leaders in neuroimaging and ADHD research"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
